Encino Team

Dr. Wanxing Chai-Ho is a hematologist oncologist who practices in Westwood and Encino. She uses a multidisciplinary approach to diagnose and treat blood disorders and solid malignancies, and is a strong advocate for her patients and their families.

Dr. Sandy Liu is a board-certified physician in oncology. She completed her oncology fellowship at UCLA and Internal Medicine residency at Cedars-Sinai Medical Center. She earned her medical degree from George Washington University in Washington D.C. and her bachelors of science in biology at University of Southern California.

Lee Rosen, MD, FACP is Health Sciences Clinical Professor of Medicine in the Division of Hematology-Oncology, Department of Medicine. He has a longstanding interest in the treatment of pancreas and other gastrointestinal malignancies, specifically in the area of new drug development. Dr. Rosen completed his residency and fellowship in hematology/oncology at the UCLA School of Medicine in 1996, joining the full-time faculty immediately thereafter. He created and directed the Cancer Therapy Development Program, designed to coordinate translational/clinical research of new cancer treatments. Some of the first drugs he and his team worked with were designed for gastrointestinal cancers, so he and colleagues created a group dedicated to treating these diseases in a coordinated fashion. He also became interested in so-called "targeted" therapy, whereby cancers could be attacked by agents with a more rational drug design and the avoidance of toxicity to normal cells. He has worked with angiogenesis inhibitors since their first appearance in the clinic and other molecules inhibiting signal transduction, others that try to harness the immune system to control cancer and still others that work by rational drug design.

Dr. John Shen is a medical oncologist who practices in Westwood, Santa Monica and Encino. He is board certified in internal medicine, and he specializes in the care of older adults with advanced cancers. His research interests include genitourinary malignancies, such as cancers of the prostate, kidney, and bladder, as well as improving access to clinical trials for older adults.